Dr. Meinrad Lugan
Member of the Management Board, B. Braun Melsungen AG
Dr. rer. nat. Meinrad Lugan, born in Oberkirch in 1964, married, one son, studied chemistry at the Albrecht-Ludwigs-University of Freiburg. He was subsequently head of the advanced organic internship of the Institute for Organic chemistry and biochemistry in Freiburg. At the same time he worked as a consultant for the chemical industry with the focus on genetic engineering and safety.
In 1994 he took over the position of head of development for a production location of the BUCK Group in the new federal states and was soon appointed as an authorized signatory and divison manager, with responsibility for the internationalization of the product range, consisting of special chemicals and production plants. From 1998 until his appointment Dr. Lugan was the managing director in the Metall-Chemie Group with the production focuses on fine chemicals, intermediates and pharmaceuticals for the worldwide market (among others fungicides, antibiotics and preparations for oncology).
In October 2000 he was appointed a member of the Management Board of B. Braun Melsungen AG. In April 2005 Dr. Lugan was moreover appointed Chief-Knowledge-Officer of B. Braun Melsungen AG.
Since March 2006 he has been a member and since April 2007 chairman of the Executive Board of the Federal Association of Medical Technology (BVMed). Dr. Lugan was confirmed in this office for a further two years in April 2018.
Since 2005 Dr. Meinrad Lugan has been an Executive Board member at the European MedTech Umbrella Association EUCOMED, unifying with EDMA to MedTech Europe in November 2016, as well as Board member of GS1 global (Barcodes, UDI). In November 2017 Dr. Lugan was elected as Treasurer and Member of the Operations Management Committee of MedTech Europe.
1 blog from the author
Posted on 11.06.2018
On May 25th, 2017, a new era began. The date marks the beginning of the Medical Device Regulation, the MDR in short. It provides a new framework for the certification of medical devices in Europe and is supposed to increase the transparency of the approval and application of medical devices, as well as to improve […]